Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Completed 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Colonic Neoplasms 2Tongue Neoplasms 1Melanoma 1Localized Resectable Adult Primary Liver Cancer 1Liver Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Chemotherapy, Adjuvant × Clear all
NCT00085579 2012-12-12

Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡